Trending Now
Party City Holdco Inc (NYSE:PRTY) is surging and here’s why
Party City Holdco Inc (NYSE:PRTY) is surging and here are few reasons
1. The shares are oversold after a...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
iBio Inc. (NYSEAMERICAN: IBIO) Announces Fiscal Q1 2022 Financial Results and...
iBio Inc. (NYSEAMERICAN: IBIO) has announced its Q1 2022 financial result and offered a corporate update. Revenues during the quarter dropped 49% YoY to...
MAKE IT MODERN
LATEST REVIEWS
NantKwest Inc. (NASDAQ:NK) And ImmunityBio Add Cohort 3 In Phase 2...
NantKwest Inc. (NASDAQ:NK) has announced the addition of a third cohort to its ongoing Phase 2 study if its novel immunotherapy for the treatment...
MAKE IT MODERN
PERFORMANCE TRAINING
Clovis Oncology Inc. (NASDAQ:CLVS) Sets out a Phase 2 Portion of the LIO-1 Trial...
Clovis Oncology Inc. (NASDAQ:CLVS) is an active participant in the development of innovative anti-cancer agents. It has a strong presence in the U.S., Europe,...
Progenity Inc. (NASDAQ: PROG) closes Avero Diagnostics Business Divesture and Receives New Patent
Progenity Inc. (NASDAQ: PROG) has announced the successful closing of the business divesture of Avero Diagnostics via an asset sale to Northwest Pathology.
Progenity closes...
Seres Therapeutics Inc (NASDAQ:MCRB) Will Report SER-109 Phase 3 Study Topline Data in August...
Seres Therapeutics Inc (NASDAQ:MCRB) (STI) reported a drop of 51.75% YoY to $6.45 million in Q2 2020.
Business update
STI expects to post SER-109 Phase 3...
Niche Technology Stocks: Audio Innovators in Focus (LOGI, HRAL, DBL, SONO)
Over the past year, five years, decade, and maybe more, the best performing space in the market is clear: technology innovators. The...
Aadi Bioscience Inc (NASDAQ: AADI) Is Dosing Patients For Its nab-sirolimus clinical trial
Aadi Bioscience Inc (NASDAQ: AADI) announced that it has begun dosing for its Phase II trial for patients aged 12 and above who have...
MAKE IT MODERN
